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Background: Small aneurysms of the abdominal aorta (3.0–5.5 cm in
diameter) often are managed by regular surveillance, rather than surgery,
because the risk of surgery is considered to outweigh the risk of aneurysm
rupture. The risk of small aneurysm rupture is considered to be low. The
purpose of this review is to summarise the reported estimates of small
aneurysm rupture rates.
Methods and findings: We conducted a systematic review of the
literature published before 2010 and identified 54 potentially eligible re-
ports. Detailed review of these studies showed that both ascertainment of
rupture, patient follow-up and causes of death were poorly reported: diag-
nostic criteria for rupture were never reported. There were only 14 studies
from which rupture rates (as ruptures per 100 person-years) were available.
These 14 published studies included 9779 patients (89% male) over the time
period 1976–2006 but only 7 of these studies provided rupture rates
specifically for the diameter range 3.0–5.5 cm, which ranged from 0 to 1.61
ruptures per 100 person-years.
Conclusions: Rupture rates of small abdominal aortic aneurysms
would appear to be low, but most studies have been poorly reported and did
not have clear ascertainment and diagnostic criteria for aneurysm rupture.
Comparison of Surveillance Versus Aortic Endografting for Small
Aneurysm Repair (CAESAR): Results from a Randomised Trial
Cao P., De Rango P., Verzini F., Parlani G., Romano L., Cieri E., for the
CAESAR Trial Group. Eur J Vasc Endovasc Surg 2011;41:13-25.
Background: Randomised trials have failed to demonstrate benefit
from early surgical repair of small abdominal aortic aneurysm (AAA) com-
pared with surveillance. This study aimed to compare results after endovas-
cular aortic aneurysm repair (EVAR) or surveillance in AAA 5.5 cm.
Methods: Patients (50–79 years) with AAA of 4.1–5.4 cm were ran-
domly assigned, in a 1:1 ratio, to receive immediate EVAR or surveillance by
ultrasound and computed tomography (CT) and repair only after a defined
threshold (diameter 5.5 cm, enlargement 1 cm /year, symptoms) was
achieved. The main end point was all-cause mortality. Recruitment is closed;
results at a median follow-up of 32.4 months are here reported.
Results: Between 2004 and 2008, 360 patients (early EVAR  182;
surveillance  178) were enrolled. One perioperative death after EVAR and
two late ruptures (both in the surveillance group) occurred. At 54 months,
there was no significant difference in the main end-point rate [hazard ratio
(HR) 0.76; 95% confidence interval (CI) 0.30–1.93; p  0.6] with Kaplan–
Meier estimates of all-cause mortality of 14.5% in the EVAR and 10.1% in
the surveillance group. Aneurysm-related mortality, aneurysm rupture and
major morbidity rates were similar. Kaplan–Meier estimates of aneurysms
growth 5 mm at 36 months were 8.4% in the EVAR group and 67.5% in
the surveillance group (HR 10.49; 95% CI 6.88–15.96; p  0.01). For
aneurysms under surveillance, the probability of delayed repair was 59.7% at
36 months (84.5% at 54 months). The probability of receiving open repair at
36 months for EVAR feasibility loss was 16.4%.
Conclusion: Mortality and rupture rates in AAA5.5 cm are low and
no clear advantage was shown between early or delayed EVAR strategy.
However, within 36 months, three out of every five small aneurysms under
surveillance might grow to require repair and one out of every six might lose
feasibility for EVAR.
Surveillance is safe for small AAA if close supervision is applied. Long-
term data are needed to confirm these results.
Clinical Trial Registration Information: This study is registered,
NCT Identifier: NCT00118573.
A Randomised Placebo-controlled Double-blind Trial to Evaluate
Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in
Abdominal Aortic Aneurysms
Dawson J.A., Choke E., Loftus I.M., Cockerill G.W., Thompson M.M. Eur
J Vasc Endovasc Surg 2011;41:28-35.
Objectives: Modulation of abdominal aortic aneurysm (AAA) expan-
sion by HMG-CoA reductase inhibitors (statins) might be linked to reduc-
ing IL-6 and MMP-9, which may be consequent on reducing plasmacholesterol. Ezetimibe is a novel cholesterol absorption inhibitor used in
combination with statins. This pilot study compared the biological effects of
ezetimibe combination therapy with simvastatin alone on parameters rele-
vant to aneurysm expansion including cytokines and proteolytic enzymes.
Design: Randomised placebo-controlled double-blind trial.
Materials & Methods: Eighteen patients scheduled for elective open
AAA repair were randomised to simvastatin 40 mg plus ezetimibe 10 mg
(n  9), or simvastatin 40 mg plus placebo (n  9), for 32.5 days (IQR
28–50.5) until the day of surgery. Total concentrations of TNF-, IL-1,
IL-6, IL-8, IL-10, MMPs-1, -2, -3, -8, -9, -12, -13, TIMP-1 and -2 were
measured in plasma, aortic wall homogenates and tissue culture explants.
Results: Two patients in the placebo arm did not undergo open repair
precluding aortic samples. Ezetimibe was associated with a significant reduc-
tion in aortic wall MMP-9 (p  0.02) and aortic wall IL-6 (p  0.02),
associated with a reduction in plasma lipids.
Conclusions: These results suggest that ezetimibe combination ther-
apy reduces aortic wall proteolysis and inflammation, key processes that drive
AAA expansion. A larger RCT is justified focussing on aneurysm growth
rates in small AAA.
Endovascular Treatment of Ruptured Thoracic Aortic Aneurysm in
Patients Older than 75 Years
Jonker F.H.W., Verhagen H.J.M., Heijmen R.H., Lin P.H., Trimarchi S.,
Lee W.A., Moll F.L., Athamneh H., Muhs B.E. Eur J Vasc Endovasc Surg
2011;41:48-53.
Objectives: To investigate the outcomes of thoracic endovascular
aortic repair (TEVAR) for ruptured descending thoracic aortic aneurysm
(rDTAA) in patients older than 75 years.
Methods: we retrospectively identified all patients treated with
TEVAR for rDTAA at seven referral centres between 2002 and 2009. The
cohort was stratified according to age75 and75 years, and the outcomes
after TEVAR were compared between both groups.
Results: Ninety-two patients were identified of which 73% (n  67)
were 75 years, and 27% (n  25) were older than 75 years. The 30-day
mortality was 32.0% in patients older than 75 years, and 13.4% in the
remaining patients (p  0.041). Patients older than 75 years suffered more
frequently from postoperative stroke (24.0% vs. 1.5%, p  0.001) and
pulmonary complications (40.0% vs. 9.0%, p  0.001). The aneurysm-
related survival after 2 years was 52.1% for patients75 years, and 83.9% for
patients 75 years (p  0.006).
Conclusions: Endovascular treatment of rDTAA in patients older than
75 years is associated with an inferior outcome compared with patients
younger than 75 years. However, the mortality and morbidity rates in
patients above 75 years are still acceptable. These results may indicate that
endovascular treatment for patients older than 75 years with rDTAA is
worthwhile.
In Situ Revascularisation with Silver-coated Polyester Prostheses and
Arterial Homografts in Patients with Aortic Graft Infection – A
Prospective, Comparative, Single-centre Study
Pupka A., Skora J., Janczak D., Plonek T., Marczak J., Szydełko T. Eur J
Vasc Endovasc Surg 2011;41:61-7.
Objective: The aim of our study was to evaluate the effectiveness of in
situ revascularisation with the use of arterial homografts and silver-coated
prostheses in the treatment of aortic graft infection.
Materials: A total of 77 consecutive patients (74 males, three females,
mean age: 58years), hospitalised between 2001 and 2008, were enrolled
into the study. Patients were assigned to three groups: group 1 (n  24) –
fresh arterial homograft with subsequent immunosuppression, group 2
(n  26) – fresh arterial homograft without immunosuppression and group
3 (n  27) – silver-coated prosthesis.
Methods: The course of infection was assessed by scintigraphy with
99mTechnetium-labelled leucocytes, Duplex–Doppler ultrasound, angio-
computed tomography (CT) and microbiological examination.
Results: The mean follow-up was 22.8 (10.1) months. There was a
significant decrease in leucocyte accumulation around the graft among all
groups (group 1: p  0.012, group 2: p  0.006 and group 3: p  0.021).
The postoperative mortality rate in groups 1,2 and 3 was 8%, 23% and 11%,
respectively. The postoperative morbidity was 35% in group 2, 16% in
group1 and 7% in group 3.
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